STOCK TITAN

Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. filed a notice for the potential sale of its common stock by an affiliate. The filing covers 7,438 shares of common stock, to be sold through Merrill Lynch on July 21, 2026, following the exercise of employee stock options via a broker-assisted cashless exercise. The covered shares have an aggregate market value of $199,884.80 based on the information provided.

The filing also lists a prior sale by Eric Warren of 104,124 shares of common stock on June 26, 2026 for total proceeds of $2,696,321.98 during the past three months.

Positive

  • None.

Negative

  • None.
Shares to be sold 7,438 shares Common stock covered for potential sale on July 21, 2026
Aggregate market value $199,884.80 Value of 7,438 common shares covered by the new notice
Past 3-month shares sold 104,124 shares Common stock sold on June 26, 2026
Past 3-month sale proceeds $2,696,321.98 Proceeds from June 26, 2026 sale of 104,124 shares
Planned sale date 07/21/2026 Scheduled date for sale of 7,438 shares
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Exercise of employee stock options financial
"Exercise of employee stock options | Mineralys Therapeutics, Inc."
Broker assisted cashless exercise financial
"Broker assisted cashless exercise"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does Mineralys Therapeutics (MLYS) disclose in this Form 144 filing?

Mineralys Therapeutics discloses a planned sale of 7,438 shares of common stock by an affiliate on July 21, 2026 after an employee stock option exercise, along with a previously completed sale during the last three months.

How many Mineralys Therapeutics (MLYS) shares are covered by the new sale notice?

The notice covers 7,438 shares of common stock of Mineralys Therapeutics, Inc. These shares relate to an exercise of employee stock options and are to be sold through Merrill Lynch in a broker-assisted cashless transaction.

What is the aggregate market value of the MLYS shares in the planned sale?

The planned sale involves shares with an aggregate market value of $199,884.80. This value applies to the 7,438 shares of common stock that may be sold through Merrill Lynch on July 21, 2026.

What prior Mineralys Therapeutics (MLYS) stock sale is disclosed for the past three months?

The filing reports that on June 26, 2026, 104,124 shares of Mineralys Therapeutics common stock were sold for total proceeds of $2,696,321.98. This transaction is listed as a sale during the past three months.

Who is the selling security holder in the recent MLYS Form 144 disclosure?

The filing identifies Eric Warren, with a Radnor, Pennsylvania address, as the related party. The document associates him with a June 26, 2026 sale of 104,124 common shares for $2,696,321.98 and the new notice to sell 7,438 shares.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature